Abbott's Cologuard Plus® Achieves CE Mark for European Colorectal Cancer Screening

Abbott's Cologuard Plus® Achieves CE Mark for Colorectal Cancer Screening

Abbott, a global leader in healthcare, has recently announced that its innovative product, Cologuard Plus®, has received the CE marking under the European Union's In Vitro Diagnostic Regulation (IVDR). This milestone paves the way for the non-invasive stool-based DNA screening test to be available across various European markets. Cologuard Plus is designed to effectively detect colorectal cancer and advanced precancerous lesions, which are critical for early intervention.

A Breakthrough in Colorectal Cancer Detection

Cologuard Plus is a state-of-the-art DNA testing method that analyzes stool samples for specific DNA markers and blood associated with colorectal cancer and precancerous lesions. One of the test's most significant advantages is that it requires no bowel preparation, dietary restrictions, or sedation, making it exceptionally convenient for patients.

This recent regulatory approval signifies Abbott's commitment to making Cologuard Plus accessible in Europe. The launch timeline and availability will vary by country, dependent on local supply chains, reimbursement policies, and operational readiness. According to Jake Orville, Abbott's Senior Vice President of Cancer Diagnostics, colorectal cancer screenings are essential in the fight against this disease, but their effectiveness relies heavily on public participation. He emphasized that Cologuard has revolutionized screening in the United States, providing an effective at-home option.

Addressing a Significant Burden

Diving into the statistics, colorectal cancer is one of the most commonly diagnosed cancers in Europe, with approximately 538,000 cases reported across the continent in 2022. Within the EU alone, more than 356,000 new cases were diagnosed, accounting for about 13% of all new cancer cases. Screening has proven to be a crucial tool in detecting colorectal cancer early, when treatment is more likely to be successful, and can identify certain precancerous stages before they progress.

However, participation in these screenings varies widely across Europe. In 2022, only about 42% of individuals in the target age group participated in colorectal cancer screenings in reporting EU member states. Dr. Cesare Hassan, a prominent gastroenterology professor at Humanitas University in Milan, stated that addressing this public health challenge is vital. He believes that providing broader access to accurate and non-invasive screening options is essential for early detection of cancers and advanced precancerous lesions.

How Cologuard Plus Works

Cologuard Plus requires patients to obtain stool samples at home without any prior bowel preparations. The test focuses on various DNA markers and blood components indicative of colorectal cancer. Unlike traditional methods, this testing process allows individuals to complete the screening at their convenience and with minimal disruption to their daily lives.

The clinical efficacy of Cologuard Plus has been demonstrated in the large-scale BLUE-C study, which included over 20,000 participants. The results highlighted that Cologuard Plus achieved a sensitivity of 95% for detecting colorectal cancer with a specificity of 94%. Additionally, it showed a sensitivity of 43% for advanced precancerous lesions and a remarkable reduction in false-positive results compared to the original Cologuard test—a significant improvement that underlines the robustness of the new screening method.

Insights into Cologuard and Cologuard Plus

Both Cologuard® and Cologuard Plus® were developed in partnership with the Mayo Clinic and are non-invasive tests for colorectal cancer screening. They are intended for adults aged 45 and over who are at average risk. A positive Cologuard Plus result could indicate the presence of colorectal cancer or advanced precancerous lesions, requiring verification through a colonoscopy.

Since its launch in the United States in 2014, the initial Cologuard test has been employed in over 23 million screenings, showcasing its impact on preventive healthcare. Cologuard Plus builds on this legacy by enhancing clinical performance and refining the testing process.

Conclusion

Abbott continues to lead in innovative healthcare solutions that aim to improve lives across all stages. By supporting early detection and preventive measures, especially for conditions like colorectal cancer, Abbott is taking significant steps towards addressing public health challenges. The CE marking for Cologuard Plus opens new avenues for colorectal cancer screenings in Europe, promising a future where more people can take charge of their health effectively and conveniently.